Eknath Deo
Hematology & Oncology · Long Beach, CANPI 1568485415
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,107 and has fallen 99.2% since, to $16 in 2025.
Across 304 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$754
- Johnson & Johnson$513
- Coherus Oncology, Inc.$507
- Incyte Corporation$358
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,84397%
- Education$1933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,272 |
| Amgen | 48 | $1,177 |
| E.r. Squibb & Sons, L.L.C. | 30 | $754 |
| Johnson & Johnson | 20 | $513 |
| Coherus Oncology, Inc. | 39 | $507 |
| Incyte Corporation | 17 | $358 |
| Merck | 16 | $310 |
| Bristol Myers Squibb | 15 | $307 |
| Novartis | 13 | $272 |
| Gilead(2 entities) | 3 | $174 |
| Pfizer | 10 | $150 |
| Astellas Pharma US Inc | 3 | $124 |
| Genentech USA, Inc. | 6 | $117 |
| Regeneron Healthcare Solutions, Inc. | 3 | $93 |
| Eisai Inc. | 4 | $91 |
| Exelixis Inc. | 3 | $79 |
| AVEO Pharmaceuticals, Inc. | 3 | $73 |
| AMAG Pharmaceuticals, Inc. | 3 | $71 |
| Bayer | 2 | $56 |
| Sanofi | 2 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $52 |
| Beigene USA, Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Clovis Oncology, Inc. | 2 | $35 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| CTI Biopharma Corp. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Morphosys, US Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,036 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Long Beach
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.